P

Pfizer

Biopharmaceutical company develops medicines and vaccines

Key Account Director - Rare Disease

Full-TimePosted on 9/30/2026Deadline 10/8/26
$176.6k - $294.3k/yr+ 20% target bonus + Share-based long-term incentive program
Expert
Bachelor's, Master's, MBA
Remote in USA+2 moreMore locations: South Carolina, USA | North Carolina, USA
RemoteExpected to live in the surrounding areas of the South and North Carolina territory. Relocation assistance may be available based on business needs or eligibility.
No H1B Sponsorship

About the job

Requirements
  • Management and/or Account Management experience is strongly recommended.
  • A Bachelor's Degree is required; an MBA or advanced degree in a related field is preferred.
  • Five to ten years of pharmaceutical, biotech, or medical marketing/sales experience is preferred, including at least three years in a promoted position and/or developmental role demonstrating leadership across peer and manager groups.
  • Rare Disease and/or Specialty Cardiovascular experience and expertise are strongly preferred.
  • Product launch experience is preferred.
  • Prior team management is preferred.
  • The candidate is expected to live in the geographic area of the role.
  • Demonstrated knowledge of the healthcare market and Rare Disease therapeutic category disease states, ability to develop and manage relationships with key accounts (C-suite and key opinion leaders), account management and negotiation skills, and ability to prioritize resources and develop business plans.
  • Ability to understand, influence, and adapt to changing local healthcare, key customer, and stakeholder needs; assess and prioritize account resources; align account needs with Pfizer goals; and develop account plans based on healthcare and local market trends.
  • Strategic planning, critical and analytical thinking, and execution and measurement of outcomes.
  • Ability to build and maintain trusting relationships, communicate persuasively orally and in writing, listen effectively, and adapt communications to audience needs.
  • Networking, stakeholder management, and influencing without authority.
  • Ability to uphold Pfizer values and compliance commitments, provide a vision for delivering organizational goals, adapt to ambiguity, stay focused on performance, and coach others through change.
  • Self-awareness and a breadth of leadership experience, including influencing and collaborating with peers, developing and coaching others, and overseeing and guiding colleagues' work to achieve outcomes.
Responsibilities
  • Develop market insights and understand market and account/customer influencers in Rare Disease therapeutic categories.
  • Manage accounts and develop relationships with C-suite, administrative, and Rare Disease therapeutic service-line leaders.
  • Develop and implement account plans for assigned accounts; identify, develop, and advance partnership opportunities between Pfizer and accounts/customers.
  • Work with Pfizer stakeholders to identify and develop appropriate Rare Disease Key Account Director opportunities.
  • Work with state, regional, or district business leaders and cross-functional Pfizer specialists to provide appropriate account support.
  • Segment and prioritize accounts and identify key customers within them, including integrated delivery networks, integrated delivery systems, accountable care organizations, medical groups, independent physician associations, professional societies, healthcare provider organizations, quality improvement organizations, and IDN specialty pharmacies in the defined distribution network.
  • Identify key customers and decision-making and influencing networks within accounts and local health economies.
  • Maintain effective relationships with key customer C-suite and Rare Disease therapeutic service-line leaders and account administrators and decision-makers.
  • Develop relationships with key opinion leaders and stakeholders in local health economies.
  • Understand and seek to influence local, regional, and national healthcare issues and best practices aligned to markets and key accounts; political and advocacy organization engagements are led by Political Affairs colleagues.
  • Manage co-execution of project plans and hold customers and Pfizer accountable for plan execution.
  • Manage prioritized accounts to achieve agreed business objectives.
  • Identify opportunities for synergy and collaboration to achieve Pfizer and customer goals through transparent account planning.
  • Analyze local environments, account business, and Pfizer priorities to create account plans identifying mutually beneficial opportunities.
  • Use Rare Disease value propositions to create mutually beneficial business opportunities and translate them into action.
  • Connect and communicate stakeholder insights to develop mutually beneficial plans of action.
  • Partner with the Rare Disease IAT to improve colleague understanding of local market and customer drivers.
  • Influence local, regional, and national Key Account Director efforts by partnering with cross-functional teams to shape compliant initiatives and deliver results.
  • Share and scale proven practices across the region and nation.
  • Lead and support the development of a high-functioning cross-functional team across sales, medical, marketing, health information technology, and integrated market access Key Account Director functions, consistent with the account team model.
  • Serve as a local expert on healthcare reform, the evolving landscape, and account/customer organization.
  • Lead development of Rare Disease account and strategic planning priorities.
  • Apply Rare Disease therapeutic-category market knowledge and healthcare dynamics that influence integrated delivery network behavior; involve colleagues from other functional areas to build and execute strategic plans that address issues or solve problems.
  • Use organizational awareness and align Pfizer priorities to involve appropriate colleagues with accounts, optimizing value for customers and Pfizer.
  • Lead pull-through activities in alignment with Pfizer business leader direction.
  • Coordinate effectively with cross-functional teams.
  • Communicate short-, mid-, and long-term Pfizer business views with key accounts, identifying ongoing Rare Disease portfolio opportunities and aligning across Pfizer business units when appropriate.
  • Provide regional marketing and strategy teams with local and customer-specific insights for developing market-specific materials.
Desired Qualifications
  • Rare Disease and/or Specialty Cardiovascular experience and expertise.
  • Product launch experience.
  • Prior team management experience.
  • Relocation assistance may be available based on business needs and eligibility.

About the company

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $15.0 billion, and management raised full-year guidance to $60.5-$62.5 billion.
  • FDA approved Pfizer's 2026-2027 XFG Comirnaty vaccine on August 28, 2026.
  • Innovent and Metsera expand Pfizer's pipeline, while non-COVID revenue grew 5% operationally in Q2.

What critics are saying

  • Eliquis loses protection by 2028, and Ibrance faces U.S. patent expiry in 2027.
  • Pfizer just cut MET-224o and PF-07976016, proving obesity execution remains fragile versus Lilly.
  • Sanofi, Arbutus, and Bayer lawsuits target mRNA and LNP royalties, while restructuring runs through 2029.

What makes Pfizer unique

  • Pfizer spans vaccines, oncology, and cardiometabolic drugs across 2026, unlike narrower peers.
  • Metsera gave Pfizer monthly GLP-1 and amylin assets, plus obesity scale overnight.
  • Its global manufacturing and distribution network keeps Comirnaty, Padcev, and Vyndaqel commercially resilient.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

↓ -3%

1 year growth

↓ -3%

2 year growth

↓ -3%
Yahoo Finance
Sep 24th, 2026
Bristol Myers Squibb vs Pfizer: which healthcare stock is a better buy in 2026?

Bristol Myers Squibb and Pfizer, two pharmaceutical giants facing patent cliffs on blockbuster drugs, are taking divergent approaches to growth. Bristol Myers focuses on oncology and immunology whilst Pfizer leverages pandemic-era cash for acquisitions in high-growth areas like obesity treatments. Bristol Myers reported FY 2025 revenue of $48.2 billion, down 0.2% year-over-year, with net income of $7.1 billion and a 14.6% net margin. The company maintains a debt-to-equity ratio of 2.6x and generated $12.8 billion in free cash flow. Pfizer's FY 2025 revenue totalled $62.6 billion, declining 1.6%, with net income of $7.8 billion and a 12.4% net margin. Recent acquisitions include Seagen and Metsera, positioning the firm in oncology and obesity markets. Both companies partner with distributors and maintain global operations across multiple therapeutic areas.

Yahoo Finance
Sep 23rd, 2026
Pfizer and Butterfly Network lead AI healthcare push with revenues up to $63.7B

Butterfly Network is commercialising AI-enhanced ultrasound devices designed to assist clinicians with real-time scan guidance. The company generates approximately $112 million in revenue from its handheld iQ devices and related software platforms, including Compass AI and ScanLab, with a market capitalisation of roughly $2.2 billion. In November 2025, Butterfly's subsidiary signed a five-year co-development and licensing agreement with Midjourney for exclusive access to its semiconductor-based ultrasound technology. The deal includes a $15 million upfront payment, $10 million in annual licence fees, and additional milestone-based payments. Pfizer, with $63.7 billion in recent revenue and a market value of $158.1 billion, is applying biomolecular AI foundation models to accelerate drug discovery and development across its Global Biopharmaceuticals Business segment. The company combines large-scale therapeutic operations with machine learning applications in molecule design, trial productivity, and manufacturing efficiency.

Yahoo Finance
Sep 20th, 2026
Pfizer CEO says major headwinds easing as drugmaker cuts $7.2B in costs, eyes oncology pipeline

Pfizer's chief executive Albert Bourla says the pharmaceutical company's major headwinds are easing. Speaking at a recent conference, Bourla identified three challenges facing the drugmaker in 2025: tariffs and drug pricing policies, declining coronavirus product sales, and patent cliffs. The company has addressed tariffs by signing agreements with the US government for reduced medicine prices in exchange for tariff breaks. Pfizer has exceeded Wall Street's earnings-per-share estimates in all 10 of its past quarterly reports, suggesting its coronavirus business no longer significantly impacts performance. However, major patent cliffs loom. Eliquis, which generated $4.6 billion in the first half of the year, could face generic competition by 2028. Cancer treatment Ibrance, with $2.1 billion in first-half revenue, faces US patent expiration in 2027. Pfizer has cut $7.2 billion in costs and expanded its pipeline through acquisitions and internal development, with new products generating $13 billion annually. The company offers a 6.2% dividend yield.

Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.